CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2018--
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that the Company will
present at the Goldman Sachs 39th Annual Global Healthcare
Conferenceon Tuesday, June 12, 2018 at 9:20 A.M. PT (12:20 P.M.
ET) in Rancho Palos Verdes, CA.
A live webcast of the presentation can be accessed on the investor page
of Sage's website at investor.sagerx.com. A replay of the webcast will
also be archived for up to 30 days on Sage's website following the
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering CNS disorders. Sage has a portfolio of novel
product candidates targeting critical CNS receptor systems, GABAA
and NMDA. Sage's lead program, a proprietary IV formulation of
brexanolone (SAGE-547), has completed Phase 3 clinical development for
postpartum depression and a New Drug Application is currently under
review with the U.S. Food and Drug Administration. Sage is developing
its next generation modulators, including SAGE-217 and SAGE-718, in
various CNS disorders. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180608005078/en/
Source: Sage Therapeutics
L. Suda, 585-355-1134